FDA Alerts

The US Food and Drug Administration recently approved a biosimilar to a drug used for the treatment of various autoimmune diseases, including rheumatoid arthritis and Crohn disease.

The US Food and Drug Administration has recently approved the first treatment option for patients with eosinophilic granulomatosis with polyangiitis.

The FDA has approved a new option for the long-term maintenance treatment of airflow obstruction in individuals with chronic obstructive pulmonary disease.

The US Food and Drug Administration recently approved a new glucagon-like peptide-1 receptor antagonist for improving glycemic control in patients with type 2 diabetes.

The FDA has approved a new indication for a drug previously approved for the treatment of adults with moderate-to-severe plaque psoriasis.

The FDA has approved a new option for the treatment of life-threatening allergic reactions, including anaphylaxis, in infants and young children.

After 2 clinical trials demonstrated its safety and efficacy, the US Food and Drug Administration approved the first complete HIV treatment regimen containing only 2 drugs.

After clinical trials demonstrated its efficacy, the US Food and Drug Administration approved a new treatment option for patients with hemophilia A who have Factor VIII inhibitors.

After a clinical trial demonstrated its efficacy, the FDA approved a new treatment option for adult and pediatric patients with a rare, inherited metabolic disorder.

The FDA has approved a new add-on maintenance treatment option for patients with severe asthma with eosinophilic phenotype.